CONNECT Trial Positive for Dexcom's Type 2 Growth Thesis

What happened

Dexcom reported positive results from its CONNECT randomized controlled trial in Type 2 diabetes, providing further clinical evidence that CGM improves outcomes in this patient population. The data strengthens the argument that CGM adoption will expand beyond insulin users, supporting Dexcom's growth thesis in non-insulin Type 2 diabetes management. This clinical win comes amid ongoing GLP-1 adoption concerns, but the trial reinforces that CGM complements rather than competes with these drugs. The positive results could accelerate payer coverage decisions and physician adoption, particularly for Dexcom's Stelo OTC biosensor and broader Type 2/non-insulin strategy. However, the stock remains constrained by the unresolved FDA warning letter and upcoming CMS competitive bidding, which temper the immediate upside from this news.

Implication

If the CONNECT trial leads to guideline inclusions and broader reimbursement, Dexcom's addressable market expands meaningfully, supporting the bull case valuation of $95. However, investors should remain focused on the February 2026 earnings call for margin and FDA updates, as the stock's valuation already partially discounts this positive narrative.

Thesis delta

The CONNECT trial results increase confidence in the Type 2/non-insulin adoption catalyst, which was a key driver of the bull case scenario. This reduces the probability of the base case and increases that of the bull case, though the bear case remains tied to regulatory and pricing risks.